EBT Medical

Executive Summary

EBT Medical is a San Diego-based medical device company pioneering neuromodulation therapies for pelvic health disorders, leveraging its discovery of the Saphenous nerve's role in pelvic function. Founded in 2018, the company is currently in Phase 1 development for overactive bladder (OAB), a condition affecting millions globally. EBT's approach offers a potentially non-pharmaceutical, minimally invasive alternative to existing treatments, which often have limited efficacy or undesirable side effects. By targeting the Saphenous nerve, EBT aims to modulate neural pathways that control bladder function, which could lead to improved outcomes and patient compliance. The company's early-stage status and focus on a large, underserved market position it for significant growth if clinical data are positive. However, as a private, pre-revenue entity, EBT faces typical early-stage risks including trial execution, regulatory hurdles, and funding requirements. The company has no disclosed funding or valuation, and its profile remains low in the biopharma ecosystem. With a novel mechanism and a clear unmet need, EBT Medical represents a high-risk, high-reward opportunity contingent on successful clinical validation and strategic partnerships.

Upcoming Catalysts (preview)

• Q4 2026Completion of Phase 1 trial for overactive bladder60% success
• Q3 2026FDA Breakthrough Device Designation or pre-submission meeting35% success
• H2 2026Strategic partnership or licensing deal with a urology-focused company25% success